ArticleScientific reports2018
The impact of non-alcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcification.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- MASLD and Atherosclerosis in Patients with Type 2 Diabetes Mellitus: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis.Open heart · 2021Pooled it
- Integrating liver and heart health: Cardiovascular risk reduction in patients with metabolic-associated steatotic liver disease.World journal of cardiology · 2025Review
- Metabolic dysfunction-associated steatotic liver disease and increased risk of atrial fibrillation in the elderly: A longitudinal cohort study.International journal of cardiology. Heart & vasculature · 2025Article
- Review
- Association of liver fibrosis with aneurysm size and mortality risk in patients undergoing open abdominal aortic aneurysm repair.Scientific reports · 2025Article
- Significance of APOB/APOA1 Ratio in the Prediction of Calcific Aortic Valve Disease.Cardiovascular therapeutics · 2025Article
- Article
- The association between healthy eating index-2015 with anthropometric, cardiometabolic and hepatic indices among patients with non-alcoholic fatty liver disease.BMC gastroenterology · 2024Article
- Adipose tissue-derived metabolite risk scores and risk for type 2 diabetes in South Asians.International journal of obesity (2005) · 2024Article
- Erratum: Addendum and Corrigendum to "Subclinical cardiovascular disease and utility of coronary artery calcium score" [IJC Heart Vasculat. 37 (2021) 100909].International journal of cardiology. Heart & vasculature · 2023Article
- Associations of NAFLD with circulating ceramides and impaired glycemia.Diabetes research and clinical practice · 2022Article
- Association between the Severity of Nonalcoholic Fatty Liver Disease and the Risk of Coronary Artery Calcification.Medicina (Kaunas, Lithuania) · 2021Article
- Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter.Canadian journal of gastroenterology & hepatology · 2021Review
- Association of non-alcoholic fatty liver disease with coronary artery calcification progression: a systematic review and meta-analysis.Przeglad gastroenterologiczny · 2021Article
- Triglyceride Glucose-Waist Circumference Better Predicts Coronary Calcium Progression Compared with Other Indices of Insulin Resistance: A Longitudinal Observational Study.Journal of clinical medicine · 2020Article
- Association between noninvasive assessment of liver fibrosis and coronary artery calcification progression in patients with nonalcoholic fatty liver disease.Scientific reports · 2020Article
- Non-alcoholic Fatty Liver Disease and Its Links with Inflammation and Atherosclerosis.Current atherosclerosis reports · 2020Review
- Triglyceride to High-Density Lipoprotein Ratio can predict coronary artery calcification.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is unclear whether non-alcoholic fatty liver disease (NAFLD) is an independent risk factor for cardiovascular disease. We examined the independent impact of NAFLD on the progression of the coronary artery calcification (CAC) score, a well-known marker of atherosclerosis progression. We examined 1,173 asymptomatic participants who underwent repeated CAC score measurement during routine health examinations. The subjects were categorised into four groups based on the presence (+) or absence (-) of NAFLD and metabolic syndrome (MetS). The progression of CAC score was defined as either incident CAC in a CAC-free population at baseline or an increase of ≥2.5 units between the baseline and the final square roots of the CAC scores of participants with detectable CAC at baseline. CAC progression was seen in 18.6% (98/526), 28.3% (77/272), 29.1% (30/103) and 32.0% (87/272) of the subjects with NAFLD(-)/MetS(-), NAFLD(+)/MetS(-), NAFLD(-)/MetS(+) and NAFLD(+)/MetS(+), respectively. The subjects with NAFLD(+)/MetS(+) and NAFLD(+)/MetS(-) had a significantly higher risk of CAC progression than those with NAFLD(-)/MetS(-) (multivariate-adjusted odds ratio [OR]: 1.76; 95% confidence interval [CI]: 1.18-2.62 and multivariate-adjusted OR: 1.53, 95% CI: 1.05-2.23, respectively). NAFLD is an independent risk factor for CAC progression, irrespective of the presence of MetS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.